Inactivation of the retinoblastoma (Rb) protein caused by gene mutation, association with oncoproteins from small DNA viruses, mutational inactivation of p16 Ink4a , or overexpression of cyclin D is a common feature of many human cancer cells and is causally associated with the aberrant proliferation control of cancer cells; whereas normal cells maintain an integrated cell cycle machinery and are subject to cell cycle checkpoint control by cyclindependent kinase (CDK) inhibitors (CKIs). To determine whether this dierence can be translated into a therapeutic advantage to protect normal cells from adverse cytotoxicity caused by chemotherapy, we established cell model systems for ecdysone-inducible expression of p16 Kip1 in SiHa cells failed to cause Rb dephosphorylation or to arrest cell cycle traversal, and such induction only minimally inhibited cell proliferation. We then compared the chemosensitivity of clones derived from these two cell lines when the CKIs were and were not induced. Induction of p16
Introduction
The development of neoplasia frequently involves inactivation of the retinoblastoma (Rb) protein and p53 tumor-suppressor pathways and disruption of cell cycle checkpoints that monitor the integrity of replication and division of mammalian cells (Sherr, 1994; Weinberg, 1991 Weinberg, , 1995 . These genetic alterations in neoplasia are often causally associated with uncontrolled proliferation of cancer cells. In the past decades, the design and concept of conventional cancer chemotherapy has been in principle based on defective control of cell cycle events in cancer cells and the quantitative dierence in the proportion of fastdividing cells between cancer cells and normal cells (Darzynkiewicz, 1995; Kohn et al., 1994) . While many chemotherapeutic drugs can successfully kill fastdividing cancer cells, the drugs unfortunately also damage several types of rapidly proliferating normal cells such as the hematopoietic precursors, intestinal cells, and hair follicle cells. This nonselective killing for rapidly proliferating normal cells often causes serious adverse eects in cancer patients, such as bone marrow suppression, anorexia (appetite loss), nausea, vomiting, diarrhea, stomatitis, and alopecia (hair loss) and thus limits the doses of these drugs that can be tolerated.
The progression of the mammalian cell cycle is driven by periodic activation of a group of nuclear enzymes called cyclin-dependent kinases (CDK) in response to various intracellular and extracellular signals (Morgan, 1995; Sherr, 1996) . Cells become committed to division at a point in mid to late G1 phase of the cell cycle (known as the restriction point) following phosphorylation of the Rb protein. The CDK inhibitors (CKIs) decelerate the cell cycle traversal by inactivating the CDKs that phosphorylate the Rb protein, and they are therefore key negative regulators of eukaryotic cell cycle traversal. , which are rarely mutated in human malignancies (Sherr, 2000; Sherr and Roberts, 1999) .
A hallmark of neoplasia is the disturbance of cell cycle controls. Although overexpression of such CKIs as p21
Waf1 and p27
Kip1 has been shown to cause increased resistance to chemotherapy in certain types of human cancer cells (Fueyo et al., 1998; Ruan et al., 1998; Schmidt et al., 2000; St Croix et al., 1996; Waldman et al., 1997) , recent studies suggested that CKIs may actually be used to protect normal cells from unwanted toxicity from chemotherapy and we may thus turn this disadvantage into a therapeutic advantage (Davis et al., 2001; Stone et al., 1996) . The rationale for such strategy is based on the hypothesis that substantial CKI-mediated chemoresistance can be found only in cells with normal Rb. In most cancer cells, the Rb pathway is inactivated. (Weinberg, 1995; Wiman, 1993) . This disturbance is often caused by infection from small DNA viruses such as the human papilloma virus (HPV), by mutational inactivation of p16
Ink4a or overexpression of cyclin D and, in a limited set of malignancies (such as retinoblastoma and osteosarcoma), by genetic mutation of the Rb gene. The inactivation of Rb allows cancer cells to evade the normal cell cycle checkpoint control, whereas normal cells have functional Rb and thus are liable to checkpoint regulation. This CKI-mediated resistance to chemotherapy might therefore be an ideal approach to protect normal cells from unwanted chemotherapyinduced toxicity in patients with Rb pathway-impaired cancer. The approach may justify a novel therapeutic strategy by concurrently treating Rb pathway-impaired human cancer with chemotherapy in combination with inhibiting CDK activity to protect normal cells from chemotherapy-induced cytotoxicity.
In this study, we employed the ecdysone-inducible expression system to ectopically express three representative CDK inhibitors, p16 Kip1 in the cells, we instead used A431 human vulvar epithelial carcinoma cells, which contain functional Rb but mutated p53 (Kwok et al., 1994) . For Rb-nonfunctional cells, we used SiHa human cervical carcinoma cells that are known to be infected with HPV (Baker et al., 1987) ; the HPV virus produces two oncoproteins, E6 and E7, that inactivate p53 and Rb, respectively (Dellas et al., 1998; Dyson et al., 1989; Funk and Galloway, 1998; Jones et al., 1997; Morozov et al., 1997; Schener et al., 1990; Verlhac et al., 1994) . HPV infection is one of the major causes of Rb inactivation in human cancer (Jones and Munger, 1996; Ludlow and Skuse, 1995; Munger et al., 1992; Vousden, 1995; zur Hausen, 1996 , and p27 Kip1 all imposed strong resistance to chemotherapy on the Rb-functional A431 cells but were much less eective in the Rbdisrupted SiHa cells. Our data provide experimental support for the novel therapeutic strategy of combining chemotherapy with inhibition of CDK as a means of chemoprotection of normal cells from chemotherapyinduced nonspeci®c cytotoxicity in patients with Rbpathway impaired cancers.
Results

Establishment of p16
Ink4a -, p21
Waf1 -, and p27
Kip1
-inducible expression clones in A431 and SiHa cells (7) (Figure 3a) . However, Western blot analysis with an anti-Rb antibody that recognized both hyperphosphorylated (inactive) and hypophosphorylated (active) Rb within the cells gave sharply dierent results (Figure 3b ). Proliferating A431 cells (including A431-p16, A431-p21, and A431-p27 clones) displayed a high proportion of hyperphosphorylated Rb, which was markedly reduced when p16 , and p27 Kip1 on chemotherapy-induced cytotoxicity in the Rb-functional A431 cell line and in the Rb-disrupted SiHa cell line. We found that the Rb-functional A431 cells were very responsive to inducible expression of CKI, whereas the Rb-disrupted SiHa cells were not. SiHa cells contain a fully integrated HPV 16 genome, including E7 (Baker et al., 1987) ; the latter abrogates the Rb-mediated checkpoint of the cell cycle by sequestering Rb from E2F through a well-de®ned motif, LxCxE (Huang et al., 1990; Jones et al., 1990) and by promoting Rb degradation through a ubiquitin-proteasome-dependent pathway Boyer et al., 1996) . In our current study, we used this HPV-mediated Rb-disrupted cell line, which bypasses the eects of p16 The intention in our current study was to establish cell models to prove the potential utility of a novel therapeutic strategy by which chemotherapy may be Kip1 in SiHa and A431 cells. SiHa and A431 cell clones were cultured for 24 h in culture medium in the absence (7) or presence (+) of 3 mM muristerone A. Cell cycle distribution was analysed by¯ow cytometry after the DNA was stained with propidium iodide. The analysis was repeated, and average values from three independent experiments are presented co-administered with CKIs in cancer cells, as a means of protecting normal cells from chemotherapy-induced cytotoxicity. We found that, in contrast to results for SiHa cells, which showed similar cytotoxic responses to both paclitaxel-and cisplatin-induced cytotoxicity with or without inducible expression of p16 Ink4a , p21
Waf1
, or p27 Kip1 , ectopic expression of these inhibitors signi®-cantly protected A431 cells from paclitaxel-or cisplatin-induced cytotoxicity. It is interesting to note that expression of these cell cycle inhibitors protected . SiHa or A431 cell clones were seeded onto 24-well plates in normal growth medium with (*) and without (*) induction of p16
Ink4a (left), p21 Waf1 (middle), or p27 Kip1 (right) by 3 mM muristerone A for 24 h. The cells were then exposed for 3 h to various doses of paclitaxel, followed by an additional 72 h culture period in normal growth medium with (*) and without (*) 3 mM muristerone A. Relative cell number was determined with an MTT assay as described in the text . SiHa or A431 cell clones were seeded onto 24-well plates in normal growth medium with (*) and without (*) induction of p16 Ink4a (left), p21 Waf1 (middle), or p27 Kip1 (right) by 3 mM muristerone A for 24 h. The cells were then exposed for 3 h to various doses of cisplatin, followed by an additional 72 h culture period in normal growth medium with (*) and without (*) 3 mM muristerone A. Relative cell number was determined with an MTT assay as described in the text A431 cells from the cytotoxic eects of two very dierent drugs. Paclitaxel is a microtubule stabilizer that acts in an M phase-dependent fashion; cisplatin is a DNA alkylating agent whose activity is cell cycleindependent. A431 cells contain a functional Rb but mutated p53 (Kwok et al., 1994) . In our other study, we transfected RKO human colon cancer cells, which contain both wild-type Rb and wild-type p53 (Kapoor and Lozano, 1998) Kip1 used in current study and we found that the expression of the cell cycle inhibitors conferred greater resistance to cell cycle-dependent drugs (5-¯uorouracil, camptothecin, and etoposide) than to cell cycle-independent drugs (cisplatin, doxorubicin, and melphalan) (Schmidt et al., 2001) . These results are apparently dierent from the observation seen in A431 cells in current study. The similar protective response to paclitaxel-and cisplatinmediated cytotoxicity seen in p16 Ink4a -, p21 Waf1 -, or p27
Kip1
-arrested A431 cells may be due to the mutated p53 status in A431 cells.
An early study showed that an IPTG-inducible expression of p16
Ink4a in H294T melanoma cells arrested cells and conferred on the cells resistance to cytotoxicity induced by methotrexate, vinblastine, and cisplatin (Stone et al., 1996) . Our current study expanded the candidates of the cell cycle inhibitors into p16 Ink4a , p21
Waf1
, or p27
Kip1 on paclitaxel-and cisplatin-induced cytotoxicity. To better justify this novel chemotherapy strategy, we employed the ecdysone-inducible expression system to obtain stable cell clones expressing p16 Ink4a , p21
Kip1
, and we compared the sensitivity of the cell clones with and without induction of these CDK inhibitors. This approach allowed an unbiased comparison between two isogenic cell populations that dier only in the expression of p16 . We compared the results in one CKI-responsive cell line and one CKI-unresponsive cell line. It would be ideal to also perform this study in nonmalignant cells; however, as mentioned in the introduction, we encountered technical diculty in obtaining nonmalignant cell clones for inducible expression of the cell cycle inhibitors, and we therefore used A431 cells instead. A caveat is that, although A431 cells contain normal Rb, the cells are supposed to dier from normal cells in some other aspects and thus may not completely represent human normal cells. Similarly, a cautious note should be made that, although HPV infection is one of the major causes of Rb inactivation in human malignancies, HPV may have other eects on the SiHa cells that we used as the Rb-nonfunctional cell model in the current study. For future studies, cell lines that contain Rb mutation such as Saos-2 may be considered.
One important study that needs to be carried out is to evaluate this therapeutic strategy in an in vivo model. Although it is possible for p16 Ink4a , p21
Waf1
Kip1 to be delivered to mice in a viral or nonviral way, an alternative approach is to use synthetic small-molecule inhibitors of CDK. In a recent study that reported very promising and interesting results, topic application of a synthetic CDK inhibitor prevented chemotherapyinduced alopecia in rats (Davis et al., 2001) . The data from our experiments suggest that the strategy of inhibiting CDK activation with natural or synthetic inhibitors may also be used systemically to protect normal cells from chemotherapy-induced adverse eects, provided that the Rb status in the cancers can be determined before the treatment. For patients with Rb-functional cancers, administration of CDK inhibitors would compromise the eect of chemotherapy and thus is not recommended for these cancer patients.
In summary, our data support the idea of a novel therapeutic strategy by using CKIs such as p16 Ink4a , p21
Waf1 , or p27 Kip1 or synthetic small-molecule CDK inhibitors as chemoprotective agents to protect normal cells from the toxic eects of chemotherapy. This strategy may also apply to other conventional therapies, such as radiation therapy, and apparently applies only to Rb-de®cient cancer cells. Given that Rb mutation/inactivation is one of most frequent genetic alterations found in human cancers, this novel chemotherapy strategy may hold great promise for improving the eectiveness of conventional chemotherapy for patients with cancer.
Materials and methods
Materials
Anti-p16
Ink4a and p27 Kip1 antibodies were from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA); anti-p21 
Cells and cell culture
SiHa human cervical carcinoma cells and A431 human epidermoid carcinoma cells were obtained from American Type Culture Collection (Manassas, VA, USA) and were maintained in DMEM supplemented with 10% fetal bovine serum, 100 units/ml penicillin G, 100 mg/ml streptomycin, and 0.25 mg/ml amphotericin B.
Construction of the inducible pIND vectors containing p16
Ink4a , p21
Waf1
Kip1
The construction of the pINDp21
Waf1 and pINDp27 Kip1 vectors was previously described (Schmidt et al., 2000) . The cDNA encoding p16
Ink4a was ampli®ed by PCR using the primers 5' at aag ctt gcc gcc atg gag ccg gcg gcg g and 3' t ata tct aga act atc ggg gat gtc tg. The PCR fragment was subcloned into the pIND vector via the restriction sites HindIII and XbaI. Kip1 was induced by 3 mM muristerone A for 24 h and was examined by Western blot analysis with speci®c antibodies.
Cell proliferation assay
A431 and SiHa cells were seeded onto six-well tissue culture plates at a density of 2610 4 cells/well in medium supplemented with 10% fetal bovine serum in the absence or presence of 3 mM muristerone A. Relative cell numbers were obtained using an MTT assay as described below.
Chemotherapy cytotoxicity assay (MTT assay)
Cells were seeded onto 24-well culture plates. After exposure of the cells to various doses of chemotherapeutic drugs and incubation for various times, relative cell number was assayed by adding 50 ml of 10 mg/ml MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) to 0.5 ml of culture medium and incubating the cells for 3 h at 378C in a CO 2 incubator, followed by cell lysis with 500 ml of lysis buer containing 20% SDS in dimethyl formamide/H 2 O (1 : 1, v/v), pH 4.7, at 378C for more than 6 h. Relative cell number was then determined by measuring the optical absorbance of cell lysates at a wavelength of 595 nm and normalizing the value with a corresponding control (untreated cells).
Immunoblot analysis
Cells were lysed in a lysis buer containing 50 mM Tris, pH 7.4, 150 mM NaCl, 0.5% NP-40, 50 mM NaF, 1 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl¯uoride, 25 mg/ml leupeptin, and 25 mg/ml aprotinin. The lysates were cleared by centrifugation, and the supernatants were collected. Equal amounts of lysate protein were used for Western blot analysis with the indicated antibodies (Fan et al., 1995) . Speci®c signals were visualized by use of the ECL chemoluminescence detection kit (Amersham, Arlington Heights, IL, USA).
Flow cytometric analysis
Cell cycle distribution analysis with propidium iodide was performed as previously described (Fan et al., 1995) . Brie¯y, upon the completion of the desired treatment, cells were harvested by trypsinization, and an aliquot (1610 6 cells) was washed once with ice-cold PBS, followed by ®xation with 2% formaldehyde in PBS for 15 min. The cells were then kept in 70% ethanol at 7208C until DNA staining. DNA was stained with a solution containing 25 mg/ml propidium iodide and 10 mg/ml RNAse A in PBS for 6 h at 378C. Cell cycle distribution was analysed with a¯ow cytometer at an excitation wavelength of 488 nm.
Rb kinase assay
The kinase assay with GST-Rb as a substrate was performed as previously described (Chou et al., 1999; Wu et al., 1996) . Brie¯y, after cell lysis, CDK2 was immunoprecipitated. The immunoprecipitates were subjected to an in vitro kinase reaction with 30 ml of reaction mixture containing 10 mCi of [g7 32 P]ATP, 20 mM unlabeled lithium ATP, and 0.2 mg of puri®ed GST-Rb protein (Santa Cruz Biotechnology, Inc.) in a kinase buer (50 mM HEPES ± KOH, pH 7.5, 10 mM MgCl 2 , 1 mM dithiothreitol, 2.5 mM EGTA, 10 mM bglycerophosphate, 0.1 mM sodium orthovanadate, 1 mM NaF). The reaction was allowed to proceed at 308C for 30 min and was then stopped by boiling the samples in SDS sample buer for 5 min; the products were separated by 10% SDS ± PAGE and then subject to autoradiography.
Abbreviations
Rb, retinoblastoma protein; CDK, cyclin-dependent kinase; HPV, human papilloma virus; GST-Rb, glutathione S-transferase-Rb fusion protein.
